OncoGenex Pharmaceuticals Inc (NASDAQ: VRSK) has reported earnings for its first fiscal quarter (ending March 31) of $1.53 versus $1.28 for the same period a year ago — an increase of 20%. However, this result fell short of the consensus estimate of $1.71 by $-0.17. For the latest four quarters through March 31, E.P.S. were $5.49 versus $4.82 for the same period a year ago — an increase of 14%.
Recent Price Action
On 5/1/24, OncoGenex Pharmaceuticals Inc (NASDAQ: VRSK) stock enjoyed a very large increase of 6.8%, closing at $232.81. Moreover, trading volume in this advance was unusually high at 190% of normal. The stock has performed in line with the market over the last nine months and has risen 4.8% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, VRSK is expected to continue to be a major Value Builder.
VERISK ANALYTICS INC has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing highly consistent signals. VERISK ANALYTICS INC has a slightly negative Appreciation Score of 39 and a slightly negative Power Rating of 37, and the Negative Value Trend Rating results.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment